NO20092662L - Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme - Google Patents

Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme

Info

Publication number
NO20092662L
NO20092662L NO20092662A NO20092662A NO20092662L NO 20092662 L NO20092662 L NO 20092662L NO 20092662 A NO20092662 A NO 20092662A NO 20092662 A NO20092662 A NO 20092662A NO 20092662 L NO20092662 L NO 20092662L
Authority
NO
Norway
Prior art keywords
physiologically active
producing
same
release composition
lactic acid
Prior art date
Application number
NO20092662A
Other languages
English (en)
Other versions
NO347209B1 (no
Inventor
Tomomichi Futo
Kazuhiro Saito
Tetsuo Hoshino
Masuhisa Hori
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39015849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092662(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20092662L publication Critical patent/NO20092662L/no
Publication of NO347209B1 publication Critical patent/NO347209B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nanotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Sammensetningen med opprettholdt frigjøring hvor et vannløselig, fysiologisk aktivt peptid hovedsakelig er uniformt dispergert i en mikrokapsel bestående av en melkesyrepolymer eller et salt derav, og den fysiologisk aktive substansen er inneholdt i en mengde på 15 til 35 vekt % i forhold til de totale mikrokapslene og vektgjennomsnittlig molekylær vekt av melkesyrepolymeren er omkring I 1 000 til omkring 27 000, som er karakterisert ved å ha et høyt innehold av den fysiologisk aktive substansen, og undertrykkelse av den initiale overdrevne frigjøringen innenfor én dag etter administrasjonen og en stabil opprettholdt medikamentfrigjøring over en lang tidsperiode, og fremgangsmåte for å produsere det samme.
NO20092662A 2006-12-18 2007-12-17 Sammensetning med forlenget frigjøring og fremgangsmåte for å produsere det samme NO347209B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87536406P 2006-12-18 2006-12-18
US91740107P 2007-05-11 2007-05-11
PCT/JP2007/074617 WO2008075762A1 (en) 2006-12-18 2007-12-17 Sustained-release composition and method for producing the same

Publications (2)

Publication Number Publication Date
NO20092662L true NO20092662L (no) 2009-09-07
NO347209B1 NO347209B1 (no) 2023-07-03

Family

ID=39015849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092662A NO347209B1 (no) 2006-12-18 2007-12-17 Sammensetning med forlenget frigjøring og fremgangsmåte for å produsere det samme

Country Status (27)

Country Link
US (3) US8921326B2 (no)
EP (1) EP2094246B1 (no)
JP (2) JP4564098B2 (no)
KR (1) KR101522035B1 (no)
CN (1) CN101563068B (no)
AR (1) AR064381A1 (no)
AU (1) AU2007335406B2 (no)
BR (1) BRPI0720582B1 (no)
CA (1) CA2671670C (no)
CL (1) CL2007003658A1 (no)
CO (1) CO6180498A2 (no)
CR (1) CR10867A (no)
DO (1) DOP2009000144A (no)
EA (1) EA016176B1 (no)
EC (1) ECSP099439A (no)
ES (1) ES2791698T3 (no)
GE (1) GEP20125597B (no)
IL (1) IL198845A (no)
MA (1) MA31006B1 (no)
MX (1) MX2009006653A (no)
MY (1) MY148370A (no)
NO (1) NO347209B1 (no)
NZ (1) NZ577281A (no)
PE (1) PE20081842A1 (no)
TN (1) TN2009000197A1 (no)
TW (1) TWI481424B (no)
WO (1) WO2008075762A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4564098B2 (ja) 2006-12-18 2010-10-20 武田薬品工業株式会社 徐放性組成物およびその製造法
UY33127A (es) * 2009-12-22 2011-07-29 Takeda Pharmaceutical Formulación de liberación sostenida
BR112012032544A2 (pt) * 2010-06-25 2016-10-11 Takeda Pharmaceutical formulação de liberação prolongada, uso de um composto, e, método para produzir a formulação de liberação prolongada.
WO2013161778A1 (ja) * 2012-04-24 2013-10-31 国立大学法人大阪大学 薬剤ナノ粒子を分散した水分散液の製造法およびその利用
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
EA201692083A1 (ru) 2014-04-16 2017-03-31 Вейкс-Фарма Гмбх Фармацевтическая композиция для ветеринарии и ее применение
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3687503A1 (en) * 2017-09-26 2020-08-05 Nanomi B.V. Method for preparing micro-particles by double emulsion technique
KR101936040B1 (ko) 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
CA3102364A1 (en) 2019-03-26 2020-10-01 Novel Pharma Inc. Long-acting fatty acid-conjugated gnrh derivatives and pharmaceutical compositions containing same
CA3143471C (en) * 2019-07-12 2023-10-31 Heeyong Lee Long-lasting formulation containing rivastigmine, and method for preparing same
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) * 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
EP0452111B1 (en) * 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
DE69316101T2 (de) * 1992-08-07 1998-10-22 Takeda Chemical Industries Ltd Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DE4342092B4 (de) 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
JPH07273447A (ja) 1994-03-29 1995-10-20 Sumitomo Kinzoku Ceramics:Kk セラミック回路基板及びその製造方法
US5763513A (en) * 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
FR2736508B1 (fr) 1995-07-13 1997-09-19 Francais Prod Ind Cfpi Nouvelle forme solide de stockage et de commercialisation pour compositions phytosanitaires et moyens pour sa preparation
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
AU5678398A (en) 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
CA2316273A1 (en) * 1998-01-16 1999-07-22 Takeda Chemical Industries, Ltd. Sustained-release composition, method of its production and use thereof
ES2214013T3 (es) 1998-03-04 2004-09-01 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
US6114495A (en) * 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6270802B1 (en) * 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
PT1158014E (pt) 1998-12-15 2005-04-29 Takeda Pharmaceutical Processo para a producao de poliesteres biodegradaveis
MXPA02000461A (es) 1999-07-15 2002-07-30 Takeda Chemical Industries Ltd Composiciones de liberacion prolongada, metodos para producir las mismas y uso de estas.
WO2001010414A1 (en) 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
US7019106B2 (en) 2000-08-07 2006-03-28 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2002043766A1 (en) 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Medicinal compositions and process for producing the same
AU2002221139A1 (en) 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
TWI332407B (en) * 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
US20050064039A1 (en) * 2001-12-26 2005-03-24 Tomomichi Futo Novel microsphere and method for production thereof
PT1532985T (pt) * 2002-06-25 2017-01-20 Takeda Pharmaceuticals Co Processo de produção de uma composição de libertação sustentada
US6803708B2 (en) * 2002-08-22 2004-10-12 Cdream Display Corporation Barrier metal layer for a carbon nanotube flat panel display
JP2008518881A (ja) 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
US20050152911A1 (en) * 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
EP3173072A1 (en) 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
EP1824460B1 (en) 2004-11-10 2014-12-24 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system
JP4564098B2 (ja) 2006-12-18 2010-10-20 武田薬品工業株式会社 徐放性組成物およびその製造法

Also Published As

Publication number Publication date
JP2010222371A (ja) 2010-10-07
US9713595B2 (en) 2017-07-25
JP5258844B2 (ja) 2013-08-07
US20150080322A1 (en) 2015-03-19
EP2094246B1 (en) 2020-04-01
NO347209B1 (no) 2023-07-03
JP4564098B2 (ja) 2010-10-20
TN2009000197A1 (en) 2010-10-18
MA31006B1 (fr) 2009-12-01
CL2007003658A1 (es) 2008-05-09
NZ577281A (en) 2011-12-22
PE20081842A1 (es) 2009-01-19
EP2094246A1 (en) 2009-09-02
TW200833376A (en) 2008-08-16
CA2671670A1 (en) 2008-06-26
CN101563068B (zh) 2013-03-20
CA2671670C (en) 2015-02-10
EA200970600A1 (ru) 2009-12-30
MX2009006653A (es) 2009-07-02
IL198845A0 (en) 2010-02-17
TWI481424B (zh) 2015-04-21
BRPI0720582A2 (pt) 2014-02-04
US20170165204A1 (en) 2017-06-15
BRPI0720582B1 (pt) 2021-08-24
KR20090094272A (ko) 2009-09-04
AU2007335406A1 (en) 2008-06-26
EA016176B1 (ru) 2012-02-28
DOP2009000144A (es) 2009-07-30
GEP20125597B (en) 2012-08-10
ECSP099439A (es) 2009-07-31
WO2008075762A1 (en) 2008-06-26
AR064381A1 (es) 2009-04-01
IL198845A (en) 2015-07-30
MY148370A (en) 2013-04-15
US20110135741A1 (en) 2011-06-09
JP2010513225A (ja) 2010-04-30
KR101522035B1 (ko) 2015-05-20
US9617303B2 (en) 2017-04-11
CN101563068A (zh) 2009-10-21
AU2007335406B2 (en) 2012-09-13
US8921326B2 (en) 2014-12-30
CR10867A (es) 2009-07-30
CO6180498A2 (es) 2010-07-19
ES2791698T3 (es) 2020-11-05

Similar Documents

Publication Publication Date Title
TN2009000197A1 (en) Sustained - release composition and method for producing the same
US12533312B2 (en) Method and system for preventing sore throat in humans
US11357722B2 (en) Method and system for preventing sore throat in humans
US10668014B2 (en) Method and system for preventing sore throat in humans
DE69940735D1 (de) Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
JP2008508339A (ja) フェニトイン製剤および創傷治癒におけるその使用
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
MXPA05012791A (es) Formulacion sostenida que contiene dimeticona.
EP2983678B1 (en) Anti-microbial composition
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
NO20083027L (no) Kontrollert frigivelses-fastformpreparat
MY151468A (en) Controlled release solid preparation
NO20062082L (no) Pellets inneholdende venlafaksinhydroklorid
JP4681713B2 (ja) フィルムコーティング組成物およびそれを用いた防臭性固形製剤
AU2020203126B2 (en) Pharmaceutical solution comprising dopamine for use in treating Parkinson's disease
PL214226B1 (pl) Preparat zawierajacy podstawione pochodne imidazolu
FR3097740A1 (fr) Bactérie de la famille des Christensenellacées et composition en contenant pour la prévention et/ou le traitement d’une perte de masse musculaire pathologique ou d’une maladie caractérisée par une perte de masse musculaire pathologique
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением
BR0215707A (pt) Composição farmacêutica para a liberação controlada de ingredientes ativos e processo para a preparação de uma composição farmacêutica
JP2014070061A5 (no)
Zhao et al. Research Progress and Interfacial Adhesion Mechanisms of Oral Delivery Systems Based on Natural Polymers
Niedrist A granular hydrogel platform for periodontal applications
JO2440B1 (en) Formulation of oral pharmaceutical polymers for controlled release of terbutalate sulfate.
BRPI1007346A2 (pt) composição farmacêutica cronoterapêutica.
JP2008100948A (ja) 硫化水素および／または硫化水素塩を含有する神経細胞分化促進剤およびその方法